These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
191 related articles for article (PubMed ID: 27775756)
1. Approving a Problematic Muscular Dystrophy Drug: Implications for FDA Policy. Kesselheim AS; Avorn J JAMA; 2016 Dec; 316(22):2357-2358. PubMed ID: 27775756 [No Abstract] [Full Text] [Related]
2. FDA Approves Eteplirsen for Duchenne Muscular Dystrophy: The Next Chapter in the Eteplirsen Saga. Aartsma-Rus A; Krieg AM Nucleic Acid Ther; 2017 Feb; 27(1):1-3. PubMed ID: 27929755 [No Abstract] [Full Text] [Related]
8. Eteplirsen Approved for Duchenne Muscular Dystrophy: The FDA Faces a Difficult Choice. Stein CA Mol Ther; 2016 Nov; 24(11):1884-1885. PubMed ID: 27916994 [No Abstract] [Full Text] [Related]
9. Exon skipping therapy for Duchenne muscular dystrophy. Kole R; Krieg AM Adv Drug Deliv Rev; 2015 Jun; 87():104-7. PubMed ID: 25980936 [TBL] [Abstract][Full Text] [Related]
10. Long-term systemic administration of unconjugated morpholino oligomers for therapeutic expression of dystrophin by exon skipping in skeletal muscle: implications for cardiac muscle integrity. Malerba A; Boldrin L; Dickson G Nucleic Acid Ther; 2011 Aug; 21(4):293-8. PubMed ID: 21851223 [TBL] [Abstract][Full Text] [Related]
11. Railroading at the FDA. Nat Med; 2016 Nov; 22(11):1193. PubMed ID: 27824816 [No Abstract] [Full Text] [Related]
12. An Overview of Recent Therapeutics Advances for Duchenne Muscular Dystrophy. Mah JK Methods Mol Biol; 2018; 1687():3-17. PubMed ID: 29067652 [TBL] [Abstract][Full Text] [Related]
13. Railroading at the FDA. Nat Biotechnol; 2016 Nov; 34(11):1078. PubMed ID: 27824847 [No Abstract] [Full Text] [Related]
14. The case for eteplirsen: Paving the way for precision medicine. Miceli MC; Nelson SF Mol Genet Metab; 2016 Jun; 118(2):70-1. PubMed ID: 27102846 [No Abstract] [Full Text] [Related]
15. Gentamicin treatment of Duchenne and Becker muscular dystrophy due to nonsense mutations. Wagner KR; Hamed S; Hadley DW; Gropman AL; Burstein AH; Escolar DM; Hoffman EP; Fischbeck KH Ann Neurol; 2001 Jun; 49(6):706-11. PubMed ID: 11409421 [TBL] [Abstract][Full Text] [Related]
16. Access and affordability for all. Sherman M Nature; 2018 Dec; 564(7735):S23. PubMed ID: 30542179 [No Abstract] [Full Text] [Related]
17. European Medicines Agency review of ataluren for the treatment of ambulant patients aged 5 years and older with Duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophin gene. Haas M; Vlcek V; Balabanov P; Salmonson T; Bakchine S; Markey G; Weise M; Schlosser-Weber G; Brohmann H; Yerro CP; Mendizabal MR; Stoyanova-Beninska V; Hillege HL Neuromuscul Disord; 2015 Jan; 25(1):5-13. PubMed ID: 25497400 [No Abstract] [Full Text] [Related]
18. Morpholinos and their peptide conjugates: therapeutic promise and challenge for Duchenne muscular dystrophy. Moulton HM; Moulton JD Biochim Biophys Acta; 2010 Dec; 1798(12):2296-303. PubMed ID: 20170628 [TBL] [Abstract][Full Text] [Related]
19. The Effectiveness and Value of Deflazacort and Exon-Skipping Therapies for the Management of Duchenne Muscular Dystrophy. Agboola F; Lin GA; Fluetsch N; Walton SM; Rind DM; Pearson SD J Manag Care Spec Pharm; 2020 Apr; 26(4):361-366. PubMed ID: 32223597 [TBL] [Abstract][Full Text] [Related]